DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Eliquis" report has been added to ResearchAndMarkets.com's offering.
Eliquis (Apixaban; Bristol-Myers Squibb/Pfizer) is an orally available factor Xa inhibitor indicated for the prevention of venous thromboembolsim.
The drug inhibits free and clot-bound factor Xa, and prothrombinase activity, and indirectly inhibits platelet aggregation induced by thrombin, thereby decreasing thrombin generation and thrombus development, thus preventing blood clots. The drug is also indicated for stroke prevention in atrial fibrillation.
Key Topics Covered
- Drug Overview
- Product Profiles
- Eliquis: Stroke prevention in atrial fibrillation (SPAF)
- Eliquis: Venous thromboembolism (VTE)
List of Figures
Figure 1: Eliquis for SPAF - SWOT analysis
Figure 2: Drug assessment summary of Eliquis for SPAF
Figure 3: Drug assessment summary of Eliquis for SPAF
Figure 4: Eliquis sales for SPAF across the US, Japan, and five major EU markets, by country, 2017-26
Figure 5: Eliquis for venous thromboembolism - SWOT analysis
Figure 6: Drug assessment summary of Eliquis for venous thromboembolism
Figure 7: Drug assessment summary of Eliquis for venous thromboembolism
Figure 8: Eliquis sales forecast for VTE in the US, Japan, and five major EU markets, by country, 2017-26
List of Tables
Table 1: Eliquis drug profile
Table 2: Eliquis pivotal trial data in SPAF
Table 3: Eliquis late-phase trial data in SPAF
Table 4: Eliquis ongoing late-phase clinical trial in SPAF
Table 5: Eliquis sales for SPAF across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 6: Eliquis drug profile
Table 7: Eliquis pivotal trial data in venous thromboembolism
Table 8: Eliquis late-phase trial data in venous thromboembolism
Table 9: Eliquis ongoing late-phase clinical trials in venous thromboembolism
Table 10: Eliquis sales for VTE in the US, Japan, and five major EU markets, by country ($m), 2017-26
For more information about this report visit https://www.researchandmarkets.com/research/bskxlh/eliquis?w=4
